Skip to content
Search

Latest Stories

RPS president says “still a very long way to go to achieve gender equity” in pharmacy

There is still a long way to go to achieve gender equality in pharmacy in both academia and profession, Royal Pharmaceutical Society (RPS) president Claire Anderson said while addressing a webinar on ‘Driving equality for women in pharmacy today (November 19).

Sharing her personal experience, Anderson, who earlier worked as an academic, said: “I was the first ever female professor in the School of Pharmacy at Nottingham when I was appointed as professor in 2003, and at that point, only 11 per cent of professors in my university were female.”


She acknowledged that the situation has changed since then, but “there's still a very long way to go to achieve gender equity in most of academia, and in pharmacy, in particular.”

She added that the profession has ensured safe spaces for women but noted that is not enough, as gender equity is vital to achieve healthier and safer societies.

“And although our work on equality, diversity and inclusion is progressing very well, I think we're still not there. It's a journey and there's much to be achieved.”

Quoting a media investigation RPS CEO Paul Bennett said that only two per cent of pharmacy business owners are women, while 13 per cent are men.

He said: “Women in senior pharmacy leadership positions across our profession have much lower numbers than they would be if they reflect the numbers of females in the profession. And the bias remains in systems and structures, that mean the gender parity is not achieved.”

He added that gender disparity issue has been highlighted for over several years now, therefore, “we hold all of us in any position of influence to champion inclusive leadership and to support women from diverse backgrounds across all levels of policy to become leaders.”

It is the moral obligation of leaders to “use their influence to champion the rights of their female colleagues to grow in their careers and advanced in positions of leadership.”

Approving the view that gender equality in the pharmacy sector is still a far-fetched dream, head of Equality & Inclusion at NHS England, Harprit Hockley said that 78 per cent of the NHS staff comprises women but “that's not reflected in our senior roles or nor is it reflected in the decision making process.”

She explained that NHS has tried to debias individuals through training but noted that “one hour to three hours of training is not going to dismantle decades of that negative narrative.”

Therefore, the thrust needs to be on bringing in systematic changes and breaking down the barriers that obstruct achieving gender equity.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less